ANNX

Company Overview — What Does Annexon, Inc. Do?

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California. Annexon, Inc. (ANNX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Douglas Love and employs approximately 60 people. With a market capitalization of $860M, ANNX is one of the notable companies in the Healthcare sector.

Annexon, Inc. (ANNX) Stock Rating — Reduce (April 2026)

As of April 2026, Annexon, Inc. receives a Reduce rating with a composite score of 32.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ANNX ranks #2,996 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Annexon, Inc. ranks #433 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ANNX Stock Price and 52-Week Range

Annexon, Inc. (ANNX) currently trades at $5.85. The stock lost $0.29 (4.7%) in the most recent trading session. The 52-week high for ANNX is $7.18, which means the stock is currently trading -18.5% from its annual peak. The 52-week low is $1.28, putting the stock 355.3% above its annual trough. Recent trading volume was 2.1M shares, reflecting moderate market activity.

Is ANNX Overvalued or Undervalued? — Valuation Analysis

Annexon, Inc. (ANNX) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.54x, versus the sector average of 2.75x.

At current multiples, Annexon, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Annexon, Inc. Profitability — ROE, Margins, and Quality Score

Annexon, Inc. (ANNX) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -91.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -69.6% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ANNX Debt, Balance Sheet, and Financial Health

Annexon, Inc. has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.68x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $139M.

ANNX has a beta of 1.11, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Annexon, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Annexon, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Annexon, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.34. Net income for the quarter was $-193M. Operating income came in at $-206M.

In FY 2025, Annexon, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.34. Net income for the quarter was $-207M. Operating income came in at $-216M.

In Q3 2025, Annexon, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.37. Net income for the quarter was $-55M. Operating income came in at $-57M.

In Q2 2025, Annexon, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.34. Net income for the quarter was $-49M. Operating income came in at $-52M.

Over the past 8 quarters, Annexon, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ANNX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ANNX Dividend Yield and Income Analysis

Annexon, Inc. (ANNX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ANNX Momentum and Technical Analysis Profile

Annexon, Inc. (ANNX) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ANNX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Annexon, Inc. (ANNX) ranks #433 out of 838 stocks based on the Blank Capital composite score. This places ANNX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ANNX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANNX vs S&P 500 (SPY) comparison to assess how Annexon, Inc. stacks up against the broader market across all factor dimensions.

ANNX Next Earnings Date

No upcoming earnings date has been announced for Annexon, Inc. (ANNX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ANNX? — Investment Thesis Summary

The quantitative profile for Annexon, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers. High volatility (stability score 29/100) increases portfolio risk.

In summary, Annexon, Inc. (ANNX) earns a Reduce rating with a composite score of 32.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANNX stock.

Related Resources for ANNX Investors

Explore more research and tools: ANNX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANNX head-to-head with peers: ANNX vs AZN, ANNX vs SLGL, ANNX vs VMD.